A Phase II Study of Cetuximab (Erbitux®) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer

We have evaluated the efficacy and safety of cetuximab plus FOLFIRI for irinotecan and oxaliplatin-refractory colorectal cancers. From September 2004 to February 2006, 31 patients with metastatic colorectal cancer were treated with cetuximab (400 mg/m(2) intravenously [IV] over 2 hr on day 1 followe...

Descripción completa

Detalles Bibliográficos
Autores principales: Koo, Dong Hoe, Lee, Jae-Lyun, Kim, Tae Won, Chang, Heung Moon, Ryu, Min-Hee, Lee, Sung Sook, Kim, Min Kyoung, Sym, Sun Jin, Lee, Jung Shin, Kang, Yoon-Koo
Formato: Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2007
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694394/
https://www.ncbi.nlm.nih.gov/pubmed/17923763
http://dx.doi.org/10.3346/jkms.2007.22.S.S98

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694394/
https://www.ncbi.nlm.nih.gov/pubmed/17923763
http://dx.doi.org/10.3346/jkms.2007.22.S.S98

Ejemplares similares